Pfizer (PFE) stock experienced a decline on Tuesday despite an improved outlook for the year, driven by robust second-quarter sales of heart-disease and cancer drugs.
Edward Jones analyst John Boylan noted that Pfizer exceeded “heightened investor expectations” in the quarter, particularly with sales from Vyndaqel and Padcev surpassing forecasts. Vyndaqel sales surged 71% to $1.32 billion, while Padcev, acquired with Seagen, generated $394 million, outperforming analysts’ projections.
Despite the dip in morning trades, Pfizer stock remains within a buy zone, currently ranging from 29.73 to 31.22, according to MarketSurge.
Pfizer Stock: $4 Billion In Expected Savings
Pfizer reported a 3% increase in sales to $13.3 billion, surpassing analysts’ expectations. Adjusted earnings also outperformed, coming in at 60 cents per share, despite an 18-cent impact from manufacturing optimization costs.
The company is on track to achieve at least $4 billion in net cost savings by the end of the year, emphasizing its focus on controlling expenses.
Pfizer’s sales were buoyed by strong performances from Vyndaqel, Padcev, and Covid treatment Paxlovid. Sales from Comirnaty, the Covid vaccine developed with BioNTech, decreased, but overall sales grew 14% excluding Paxlovid and Comirnaty.
Hiked Guidance ‘Appears Conservative’
Pfizer raised its guidance for the year, projecting sales of $59.5 billion to $62.5 billion and adjusted earnings of $2.45 to $2.65 per share. The updated guidance was viewed as conservative by analysts, but the company’s performance remains strong.
For more updates, follow Allison Gatlin on X, at @IBD_AGatlin.
YOU MAY ALSO LIKE:
- Edwards Crashes 31% After Slashing Guidance For Its Biggest Moneymaker
- Bristol Myers Retakes Its 200-Day Line On Quarterly Beat, Surprise Immunology Win
- Want More IBD Insights? Subscribe To Our Investing Podcast!
- Find The Best Long-Term Investments With IBD Long-Term Leaders
- Join IBD Live For Stock Ideas Each Morning Before The Open